Immuron Ltd — Board/Management Information 2015

Apr 1, 2015

==> picture [192 x 42] intentionally omitted <==

IMMURON APPOINTS DR. LEEARNE HINCH AS NEW CHIEF EXECUTIVE OFFICER

2 April 2015, Melbourne, Australia: Australian biopharmaceutical company Immuron Limited (ASX: IMC), is pleased to announce the appointment of Dr Leearne Hinch as Chief Executive Officer, effective immediately.

Dr Leearne Hinch is a biotechnology executive and consultant with over 20 years’ experience in the lifescience industry, with particular strengths in general management, strategy, fundraising, technology commercialisation, business development and marketing. Most recently, Leearne was director of Ingeneus Solutions that provides strategic advice and commercialisation expertise to assist clients to protect, fund, develop and commercialise lifescience technologies. She previously held C-level executive and management positions in ASX-listed biotechnology, multinational and private companies including OBJ Ltd, Holista CollTech Ltd, Milne AgriGroup, Virbac (Australia) and Mars Petcare UK.

Leearne has strategic, operational and scientific experience leading and managing the development and commercialisation of multiple drug, device, complementary medicine and animal health products. She has a proven track record in leadership, driving performance and achieving results including advancing development milestones, raising funds and securing partners to deliver organisational growth, increased revenues and improved valuations. Leearne holds a Master of Business Administration from Curtin University, Bachelor of Science and Bachelor of Veterinary Medicine and Surgery degrees from Murdoch University, and is a member of the Commercialisation Australia Expert Network.

Regarding her appointment, Leearne said: “I am very excited to join Immuron at this important stage in its development, and look forward to working with the Board and management to realize the full potential of Immuron’s hyperimmune colostrum technology, drive the successful commercialisation of Travelan globally, and advance the NASH/ASH clinical trials towards the Phase 2 milestone”.

Immuron Chairman Dr Roger Aston said: “The Board welcomes Leearne to Immuron as CEO. She has the leadership, technical and commercial experience to lead the Company forward as we globalise our Travelan business and progress our development programs.”

The Board of Immuron thanks interim CEO Mr Amos Meltzer CEO for his contribution to the development of Immuron during the last 4.5 years.

Contacts:

Dr Roger Aston Investor Relations Chief Executive Officer Amanda Loh, Buchan Consulting +61 (0)3 9824 5254 +61 (0)3 9866 4722

Page 1 of 2

==> picture [114 x 27] intentionally omitted <==

About Immuron

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron’s technology platform products all have a very high safety profile. The company’s current products and product candidates address infectious diseases of the gastrointestinal tract as well as chronic diseases. Immuron has an on-market product, Travelan®, for preventing travellers’ diarrhoea. Immuron also has a phase 2 clinical product candidate for the treatment of inflamed fatty liver disease, known as Non-Alcoholic Steatohepatitis or NASH. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).

About Travelan®

Travelan® is clinically-proven to prevent with up to 90% efficacy the main cause of travellers’ diarrhoea. Travelan® is a natural product derived from bovine colostrum enriched with antibodies reactive to ETEC, the most common cause of travellers' diarrhoea. In clinical trials, Travelan[®] showed efficacy of up to 90% in protecting against infection with the type of E.Coli that causes travellers' diarrhoea. In addition, trials showed a significant reduction in abdominal cramps and stomach pain compared to those who did not receive Travelan[®] . Additionally, Travelan® is enriched with antibodies against lipopolysaccharides, which are bacteria-borne endotoxins that drive systemic chronic inflammation.

Page 2 of 2